# Subcutaneous Interval Lengthening of Vedolizumab for Economic Research

> **NCT06584162** · PHASE4 · RECRUITING · sponsor: **Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)** · enrollment: 40 (estimated)

## Conditions studied

- Inflammatory Bowel Diseases

## Interventions

- **DRUG:** Vedolizumab Injection

## Key facts

- **NCT ID:** NCT06584162
- **Lead sponsor:** Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-02-09
- **Primary completion:** 2025-01-01
- **Final completion:** 2026-02-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2024-09-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06584162

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06584162, "Subcutaneous Interval Lengthening of Vedolizumab for Economic Research". Retrieved via AI Analytics 2026-06-29 from https://api.ai-analytics.org/clinical/NCT06584162. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*